#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO) effective 26 October 2022), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that positive data from a peer-reviewed study evaluating the in vitro efficacy of FLU-v, Imutex Limited’s (“Imutex”) broad spectrum influenza vaccine, has been published in the scientific journal Vaccines.1 Previous clinical studies have demonstrated that FLU-v induced increased…

#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate December 6, 2021 – Posted in: Blog, Poolbeg Pharma (POLB)

6 December 2021 – Poolbeg Pharma (AIM: POLB), ‘Poolbeg’ or the ‘Company’, a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor Siobhán McClean , through NovaUCD, the university’s knowledge transfer office. The Company will continue its due diligence on MelioVac, a preclinical asset and recipient of a Wellcome Trust Award to aid its…

#ORPH Open Orphan plc – Positive in vitro results for FLU-v published September 30, 2022 – Posted in: Blog, Open Orphan (ORPH)

#POLB Poolbeg Pharma – Poolbeg signs option for new vaccine candidate December 6, 2021 – Posted in: Blog, Poolbeg Pharma (POLB)

Address

Contact

Social

LEGAL